New Drug to Target Alpha-Synuclein

New Drug to Target Alpha-Synuclein
Scientists at Dundee University have partnered with the Korean-based Bukwang Pharmaceutical Company in an effort to develop a drug which blocks an enzyme called USP8 - the enzyme prevents the natural breakdown of the toxic protein alpha-synuclein, a known contributory factor in Parkinson's.   Working with Dr George Tofaris, at Oxford University, the drug development unit at Dundee University has identified ... read more
Source: The Cure Parkinson’s TrustPublished on 2019-07-04